SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TinfoilHat who wrote (874)2/18/2025 12:02:47 PM
From: Huggenberg3 Recommendations

Recommended By
mannamal
slimchance
urslor

   of 1229
 
Troculeucel (SNK01) and M-ceNK are both types of activated autologous NK cells. With Troculeucel, the NK-cells are activated with an IL-2-like novel peptide, which reduces the side effects of IL-2. M-ceNK is activated by a combination of IL-12, IL-15 (Anktiva), and IL-18. Both Troculeucel and Anktiva are mentioned as replacements or alternatives for IL-2.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News